RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built in RSS readers, or you can use our feeds in an RSS reader or aggregator.
Investors
Corporate Profile
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.
'